Comparison between two fat emulsions: Intralipid 30 cent vs intralipid 10 cent in critically ill patients.
Fat emulsions, Intralipid 30% and Intralipid 10% were compared in terms of the resulting plasma levels of different lipid components and clinical tolerance in critically-ill patients with multi-injuries. Sixteen critically-ill patients with severe systemic inflammatory response were randomly assigned to two groups, each one comprised of eight patients. Each group was administered the same quantity of fat/Kg/day either Intralipid 30% or Intralipid 10%. The infusion lasted 12|h daily for 6 days. During the infusion of the fat emulsion, a lower median plasma concentration of triglycerides, phospolipids and free cholesterol was observed in patients who received Intralipid 30% compared with those who received Intralipid 10%. The above observations were sustained 4 h after the termination of the infusion. Free fatty acids had a higher mean plasma concentration in the group of patients who received Intralipid 30%. There were no differences between the two groups as far as the median plasma concentration of cholesterol and lipoproteins (LDL, HDL, VLDL) are concerned. On the contrary, there was an increase in LpX in the Intralipid 10% group. From the above findings, we draw the conclusion that Intralipid 30% revealed better profiles of different lipid components than Intralipid 10% in critically-ill patients. The new emulsion of higher concentration in triglyceride was proved clinically safe and its use is suggested for critically-ill patients who require total parenteral nutrition.
Kalfarentzos
F
F
Department of Surgery, Nutritional and Metabolic Unit, Department of Anaesthesiology and Critical Care Medicine, Department of Biochemistry, University Hospital of Patras, Greece.
Kokkinis
K
K
Leukaditi
K
K
Maroulis
J
J
Onoufriou
A
A
Alexopoulos
K
K
D000328:Adult; D002784:Cholesterol / Q000097:blood; D016638:Critical Illness / Q000628:therapy*; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000628:therapy; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010289:Parenteral Nutrition, Total; D010743:Phospholipids / Q000097:blood; D015599:Trauma Severity Indices; D014280:Triglycerides / Q000097:blood; D014947:Wounds and Injuries / Q000150:complications / Q000628:therapy
D005217:Fat Emulsions, Intravenous; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol